Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
Authorsvan Rhee, F
van de Velde, H
AffiliationMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
MetadataShow full item record
AbstractMulticentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated production of interleukin 6. No randomised trials have been done to establish the best treatment for the disease. We assessed the safety and efficacy of siltuximab-a chimeric monoclonal antibody against interleukin 6-in HIV-negative patients with multicentric Castleman's disease.
CitationSiltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. 2014, 15 (9):966-74 Lancet Oncol
JournalThe Lancet Oncology